The stock of FOXO Technologies Inc. (AMEX:FOXO) last traded at $0.15, down -10.63% from the previous session.
FOXO stock price is now -17.28% away from the 50-day moving average and -63.83% away from the 200-day moving average. The market capitalization of the company currently stands at $8.26M.
In other news, Dowling Vincent J. Jr, 10% Owner sold 3,000 shares of the company’s stock on Jul 14. The stock was sold for $491 at an average price of $0.16. Upon completion of the transaction, the 10% Owner now directly owns 4,647,405 shares in the company, valued at $0.7 million. Insiders disposed of 635,500 shares of company stock worth roughly $95325.0 over the past 1 year. A total of 4.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FOXO stock. A new stake in FOXO Technologies Inc. shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $14,000. HRT FINANCIAL LP invested $2,000 in shares of FOXO during the first quarter. In total, there are 20 active investors with 14.60% ownership of the company’s stock.
With an opening price of $0.1600 on Thursday morning, FOXO Technologies Inc. (AMEX: FOXO) set off the trading day. During the past 12 months, FOXO Technologies Inc. has had a low of $0.12 and a high of $11.00. The fifty day moving average price for FOXO is $0.1734 and a two-hundred day moving average price translates $0.4031 for the stock.
The latest earnings results from FOXO Technologies Inc. (AMEX: FOXO) was released for Jun, 2023. The company reported revenue of $12000.0 for the quarter, compared to $39000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -69.23 percent.
FOXO Technologies Inc.(FOXO) Company Profile
FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and FOXO Life, a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with the Longevity Report. The company was founded in 2020 and is based in Minneapolis, Minnesota. FOXO Technologies Inc. is a subsidiary of FOXO Management LLC.
